HTAs need trial data on current drugs to do a proper job, EMA told
This article was originally published in Scrip
Executive Summary
The European health technology assessment network, EUnetHTA, has strongly backed the European Medicines Agency's plans for the proactive publication of clinical trial data, but says the policy must be extended to existing drugs rather than just those submitted for approval from next year, otherwise HTA bodies will not be able to do their work properly.